CD79A and breast carcinoma: demonstrated that MUC1, a tumor-associated antigen in breast cancer, triggers a robust immune response, marked by the production of anti-glycoprotein serum IgG, IgA, and IFNɣ, effectively mobilizing the immune system against breast cancer proliferation and invasion (165).